Rybelsus (semaglutide tablets): uses, dosing, side effects and cost
Rybelsus is a once-daily semaglutide tablet from Novo Nordisk for adults with type 2 diabetes. It lowers blood sugar and, since late 2025, is labeled to cut major cardiovascular events in high-risk adults. It is not a weight-loss drug. In 2026 Novo began replacing it with Ozempic tablets, which use different milligram strengths.
Quick facts
- Active ingredient
- Semaglutide, with the absorption enhancer salcaprozate sodium (SNAC)
- Maker
- Novo Nordisk
- FDA approval
- On the US market since September 2019 (DailyMed listing); cardiovascular indication added October 2025 (label)
- Approved for
- Adults with type 2 diabetes: blood sugar control, and lowering MACE risk in those at high cardiovascular risk
- Form
- Oval tablet, swallowed whole, bottles of 30
- How often
- Once daily, on waking, with up to 4 oz of plain water, then a 30-minute wait
- Dose strengths
- 3 mg (start only), 7 mg, 14 mg. Ozempic tablets 1.5, 4 and 9 mg share the label but are a separate product
- Boxed warning
- Yes. Rodent thyroid C-cell tumors; contraindicated with MTC history or MEN 2
- Self-pay price
- No NovoCare self-pay price for Rybelsus; Ozempic tablets from $149 a month (NovoCare Pharmacy, checked 5 Oct 2026)
- Generic available?
- No. DailyMed lists no generic semaglutide tablet (checked 5 Oct 2026)
What it is
Rybelsus was the first GLP-1 receptor agonist sold as a pill; before it, the class was injection-only (rybelsus.com). Each tablet holds semaglutide, the same molecule as the Ozempic and Wegovy injections, plus salcaprozate sodium (SNAC), which helps the peptide get through the stomach lining. Even so, the label puts absolute bioavailability at only about 0.4% to 1%, which is why the tablet doses are far larger than injected ones.
The current FDA label is shared by two products. Rybelsus comes in 3, 7 and 14 mg oval tablets. Ozempic tablets (often called the Ozempic pill) are a reformulated version in 1.5, 4 and 9 mg round tablets that reach similar blood levels. NovoCare now tells patients that "Rybelsus is being replaced by Ozempic pill", and an Illinois Medicaid notice of 21 May 2026 reports that wholesaler shipments of Rybelsus stopped in May 2026, with stock becoming limited from July.
How it works
Semaglutide copies GLP-1, a gut hormone released after meals. The label explains that it raises insulin release and lowers glucagon only when blood glucose is high, so on its own it rarely causes hypoglycemia. It also slows how fast food leaves the stomach early after a meal, which blunts the post-meal glucose spike and is the main reason for nausea and fullness.
Albumin binding gives semaglutide a half-life of about one week, so even a daily tablet builds up gradually: the label reports steady-state levels after 4 to 5 weeks. Absorption happens mostly in the stomach, and food, coffee or a large glass of water in the stomach reduce it. That is the reason for the strict morning routine described on our how to take Rybelsus guide.
Approved uses
The label lists two uses, both in adults with type 2 diabetes:
- Blood sugar control, alongside diet and exercise.
- Reducing the risk of major adverse cardiovascular events (a composite of heart attack, stroke and cardiovascular death, counting only non-fatal heart attacks and strokes) for those at high risk. This indication dates from October 2025.
Rybelsus is not approved for type 1 diabetes, for children, or for weight loss. Weight did fall modestly in the diabetes trials, but the product approved for weight management in tablet form is a different one: the Wegovy pill (oral semaglutide 25 mg). See our Wegovy pill page.
What the evidence shows
The label's efficacy data come from the PIONEER program and the SOUL outcomes trial, all run with the original 3, 7 and 14 mg tablets.
- PIONEER 1 (monotherapy, 26 weeks): HbA1c fell 1.2 points on 7 mg and 1.4 on 14 mg, against 0.3 on placebo, from a baseline near 8.0%. Average weight change was -2.3 kg and -3.7 kg versus -1.4 kg.
- PIONEER 2: 14 mg lowered HbA1c 1.3 points, versus 0.9 with empagliflozin 25 mg.
- PIONEER 3: 1.0 and 1.3 points on 7 and 14 mg, versus 0.8 with sitagliptin 100 mg.
- PIONEER 4: 14 mg was non-inferior to liraglutide 1.8 mg injection (-1.2 versus -1.1).
- PIONEER 6 (3,183 people, about 16 months): no increase in cardiovascular risk (hazard ratio 0.79).
- SOUL (9,650 people, about 4 years): 14 mg cut first major cardiovascular events to 12.0% from 13.8% on placebo, a hazard ratio of 0.86.
These are trial averages; individual responses differ.
Dosing overview
Rybelsus starts at 3 mg once daily for 30 days, a dose the label says does not control glucose and exists only to build tolerance. It then steps up to 7 mg. From day 61, a prescriber may keep 7 mg or move to 14 mg, the highest strength. One tablet a day is the limit.
Ozempic tablets follow the same 30-day pattern at 1.5, 4 and 9 mg. The two products are not interchangeable milligram for milligram: the label pairs 7 mg Rybelsus with 4 mg Ozempic tablets, and 14 mg with 9 mg. The full table, switching rules and missed-dose advice are on the Rybelsus dosage page.
Side effects overview
Stomach and bowel effects dominate. In the label's two placebo-controlled trials, nausea affected 11% on 7 mg and 20% on 14 mg (6% on placebo), abdominal pain 10% and 11%, and diarrhea 9% and 10%. Decreased appetite, vomiting and constipation each reached 5% to 9%. Most nausea, vomiting and diarrhea happened while the dose was being raised, and 8% of people on 14 mg stopped treatment because of GI effects.
Serious but less common risks in the label include pancreatitis, gallbladder disease, kidney injury from dehydration, severe allergic reactions, worsening diabetic retinopathy, low blood sugar when combined with insulin or a sulfonylurea, and aspiration during anesthesia. Rates and warning signs are on the Rybelsus side effects page.
Who should not take it
Three groups must not use Rybelsus, per its label: people whose own or family medical history includes medullary thyroid carcinoma (MTC), people with multiple endocrine neoplasia type 2 (MEN 2), and people who previously reacted severely to semaglutide or an excipient in the tablet.
It is not recommended with severe gastroparesis, and breastfeeding is not recommended because SNAC passes into breast milk. For a planned pregnancy, the label wants Rybelsus stopped two months or more beforehand. Extra care, not a ban, applies to people with past pancreatitis, diabetic retinopathy or a reaction to another GLP-1 drug. Kidney and liver disease do not change the dose.
Cost and access
Novo Nordisk sells no self-pay version of Rybelsus through NovoCare. Its replacement, Ozempic tablets, is sold there on self-pay for $149 (1.5 mg), $199 (4 mg) or $299 (9 mg) per 30 tablets (NovoCare Pharmacy, checked 5 Oct 2026). If a commercial plan covers Rybelsus, Novo's offer can lower a fill to $25, with no more than $100 off per month (rybelsus.com, checked 5 Oct 2026). Medicare and Medicaid patients cannot use it.
At retail, SingleCare reports an average cash price of $1,289 for 30 tablets of 14 mg (updated 10 Sep 2026). Novo will cut the list price to $675 a month from 1 January 2027.
Temi does not fill Rybelsus or Ozempic tablets. A Temi physician can review refills of other non-controlled medicines for $15 (usetemi.com/prescription/refills, checked 5 Oct 2026). Full numbers are on the Rybelsus cost page.
More on this medication
- Rybelsus interactions
Levothyroxine, insulin, sulfonylureas, other morning tablets and the 30-minute rule.
- Rybelsus questions
Short answers to the questions people search most, each linked to the full explanation.
- How to take Rybelsus
The empty-stomach, 4-ounce water, 30-minute routine, step by step.
Frequently asked questions
Is Rybelsus being discontinued?
The Rybelsus name is being retired in the US. NovoCare states that Rybelsus is being replaced by the Ozempic pill, and Illinois Medicaid reported on 21 May 2026 that Novo Nordisk would discontinue all Rybelsus strengths, with wholesaler shipments ending in May 2026. The medicine itself, oral semaglutide, continues as Ozempic tablets. Moving over needs a new prescription at a different strength.
Can I still fill a Rybelsus prescription?
Possibly, while stock lasts. Illinois Medicaid reported that wholesaler shipments of Rybelsus stopped in May 2026 and that remaining inventory would become limited from July 2026. If your pharmacy cannot get it, ask your prescriber for a new prescription for Ozempic tablets at the matching strength. How the tablet compares with the weekly injection is covered in our Rybelsus vs Ozempic comparison.
Does Rybelsus cause weight loss?
Some, on average, but it is not approved for it. In PIONEER 1, people on 14 mg lost an average of 3.7 kg over 26 weeks, compared with 1.4 kg on placebo. In PIONEER 4, the 14 mg average was 4.4 kg. Those are diabetes-trial averages, not a prediction for any one person. The approved oral semaglutide for weight management is the Wegovy pill.
How long does Rybelsus take to work?
Blood sugar starts to respond within weeks, but the first month is a 3 mg lead-in that the label says is not effective for glucose control. Semaglutide then needs 4 to 5 weeks at each dose to reach steady levels. The trials measured HbA1c at 26 weeks, so prescribers usually judge the effect over months rather than days.
Can Rybelsus be taken with metformin?
Yes. PIONEER 2, 3 and 4 added Rybelsus to metformin, 76% of SOUL participants were on metformin at baseline, and the label's drug-interaction study found no meaningful change in metformin levels. The combination rarely causes low blood sugar on its own. That changes if insulin or a sulfonylurea is added, when the label suggests the prescriber consider lowering those doses.
Is there a generic Rybelsus?
No. DailyMed lists no generic semaglutide tablet as of 5 October 2026, and the only oral semaglutide products on it are Novo Nordisk's Rybelsus, Ozempic tablets and Wegovy tablets. Compounded semaglutide tablets are not generic Rybelsus: they are not FDA-approved and have not been tested in the PIONEER trials.
Sources
- Rybelsus and Ozempic tablets (semaglutide) prescribing information and Medication Guide, DailyMed (NLM, SPL version 14, revised 1/2026) (checked October 5, 2026)
- Rybelsus prescribing information (Novo Nordisk, revised 1/2026) (checked October 5, 2026)
- PIONEER 6: cardiovascular safety of oral semaglutide (NCT02692716), ClinicalTrials.gov (checked October 5, 2026)
- SOUL: a heart disease study of semaglutide in patients with type 2 diabetes (NCT03914326), ClinicalTrials.gov (checked October 5, 2026)
- Rybelsus savings and support: 'Rybelsus is being replaced by Ozempic pill', NovoCare (Novo Nordisk) (checked October 5, 2026)
- Rybelsus frequently asked questions, rybelsus.com (Novo Nordisk) (checked October 5, 2026)
- Ozempic pill and pen self-pay and savings prices, NovoCare Pharmacy (Novo Nordisk) (checked October 5, 2026)
- Rybelsus savings offer terms, rybelsus.com (Novo Nordisk) (checked October 5, 2026)
- Provider notice: Rybelsus discontinuation and transition to Ozempic tablets, Illinois Department of Healthcare and Family Services (21 May 2026) (checked October 5, 2026)
- How to save on Rybelsus prescriptions in 2026, SingleCare (updated 10 Sep 2026) (checked October 5, 2026)
- Novo Nordisk lowers US list price of Wegovy, Ozempic and Rybelsus to $675 a month from 1 January 2027 (Novo Nordisk Inc. press release, 24 Feb 2026) (checked October 5, 2026)
- Prescription refills, usetemi.com (checked October 5, 2026)
Compounded semaglutide and compounded tirzepatide are not FDA-approved generics of the brand-name products. A licensed 503A compounding pharmacy prepares each one for a single prescription.
Get started
Start online, and a licensed physician reviews your request
A short online questionnaire is the first step. No appointments and no insurance needed.
A licensed physician reviews every request. Nothing on this page is a prescription.